Bristol Myers pays $350M upfront for rights to heart drug Camzyos in Asia

Bristol Myers Squibb is setting up a deal with Shanghai-based LianBio to get the rights to the heart drug Camzyos in China and several other Asian countries after buying the drug’s developer in 2020.

The companies announced Tuesday that Bristol Myers will pay LianBio $350 million upfront in exchange for the rights to develop and commercialize Camzyos, or mavacamten, in mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Early Smoking Cessation After Cancer Diagnosis Tied to Better Survival

Smokers who quit after a cancer diagnosis had increased survival, with the greatest benefit for those who initiated smoking cessation treatment within 6 months, a

November 1, 2024

Study links fine particulate matter exposure to increased risk of gestational diabetes

Researchers assesses the relationship between exposure to fine particulate matter and the risk of gestational diabetes mellitus.

August 22, 2024

Another biotech scoops up asset from China-based Keymed and nabs $180M

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets

January 11, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.